1. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. (1st June 2022) Authors: Augustin, Matthias; Reich, Kristian; Yamauchi, Paul; Pinter, Andreas; Bagel, Jerry; Dahale, Swapnil; You, Ruquan; Bruin, Gerard; Djimopoulos, Jimena; Paguet, Bertrand; Charef, Pascal; Patekar, Manmath; Keefe, Deborah Journal: British journal of dermatology Issue: Volume 186:Number 6(2022) Page Start: 942 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. (8th April 2022) Authors: Augustin, Matthias; Reich, Kristian; Yamauchi, Paul; Pinter, Andreas; Bagel, Jerry; Dahale, Swapnil; You, Ruquan; Bruin, Gerard; Djimopoulos, Jimena; Paguet, Bertrand; Charef, Pascal; Patekar, Manmath; Keefe, Deborah Journal: British journal of dermatology Issue: Volume 186:Number 6(2022) Page Start: 942 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗